Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2022

Open Access 01-12-2022 | Cardiac Resynchronization Therapy | Research

Effect of single ventricular premature contractions on response to cardiac resynchronization therapy

Authors: Eperke Dóra Merkel, András Mihaly Boros, Walter Richárd Schwertner, Anett Behon, Attila Kovács, Bálint Károly Lakatos, László Gellér, Annamária Kosztin, Béla Merkely

Published in: BMC Cardiovascular Disorders | Issue 1/2022

Login to get access

Abstract

Background

We lack data on the effect of single premature ventricular contractions (PVCs) on the clinical and echocardiographic response after cardiac resynchronization therapy (CRT) device implantation. We aimed to assess the predictive value of PVCs at early, 1 month-follow up on echocardiographic response and all-cause mortality.

Methods

In our prospective, single-center study, 125 heart failure patients underwent CRT implantation based on the current guidelines. Echocardiographic reverse remodeling was defined as a ≥ 15% improvement in left ventricular ejection fraction (LVEF), end-systolic volume (LVESV), or left atrial volume (LAV) measured 6 months after CRT implantation. All-cause mortality was investigated by Wilcoxon analysis.

Results

The median number of PVCs was 11,401 in those 67 patients who attended the 1-month follow-up. Regarding echocardiographic endpoints, patients with less PVCs develop significantly larger LAV reverse remodeling compared to those with high number of PVCs. During the mean follow-up time of 2.1 years, 26 (21%) patients died. Patients with a higher number of PVCs than our median cut-off value showed a higher risk of early all-cause mortality (HR 0.97; 95% CI 0.38–2.48; P = 0.04). However, when patients were followed up to 9 years, its significance diminished (HR 0.78; 95% CI 0.42–1.46; P = 0.15).

Conclusions

In patients undergoing CRT implantation, lower number of PVCs predicted atrial remodeling and showed a trend for a better mortality outcome. Our results suggest the importance of the early assessment of PVCs in cardiac resynchronization therapy and warrant further investigations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cleland JG, Daubert JC, Erdmann E, et al. Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRef Cleland JG, Daubert JC, Erdmann E, et al. Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.CrossRef
2.
go back to reference Bristow MR, Saxon LA, Boehmer J, et al. COMPANION investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.CrossRef Bristow MR, Saxon LA, Boehmer J, et al. COMPANION investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.CrossRef
3.
go back to reference Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.CrossRef Moss AJ, Hall WJ, Cannom DS, et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.CrossRef
4.
go back to reference Brignole M, Auricchio A, Baron-Esquivias G, et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–329.CrossRef Brignole M, Auricchio A, Baron-Esquivias G, et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34:2281–329.CrossRef
5.
go back to reference Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1469–75.CrossRef Hayes DL, Boehmer JP, Day JD, et al. Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm. 2011;8:1469–75.CrossRef
6.
go back to reference Cheng A, Landman SR, Stadler RW. Reasons for loss of cardiac resynchronization therapy pacing: insights from 32 844 patients. Circ Arrhythm Electrophysiol. 2012;5:884–8.CrossRef Cheng A, Landman SR, Stadler RW. Reasons for loss of cardiac resynchronization therapy pacing: insights from 32 844 patients. Circ Arrhythm Electrophysiol. 2012;5:884–8.CrossRef
7.
go back to reference Ruwald MH, Mittal S, Ruwald AC, et al. Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. J Am Coll Cardiol. 2014;64:971–81.CrossRef Ruwald MH, Mittal S, Ruwald AC, et al. Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. J Am Coll Cardiol. 2014;64:971–81.CrossRef
8.
go back to reference Dickstein K, Vardas PE, Auricchio A, et al. Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010;31:2677–87.CrossRef Dickstein K, Vardas PE, Auricchio A, et al. Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010;31:2677–87.CrossRef
9.
go back to reference Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRef Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63.CrossRef
10.
go back to reference Akkaya M, Roukoz H, Adabag S, et al. Improvement of left ventricular diastolic function and left atrial reverse remodeling after catheter ablation of premature ventricular complexes. J Interv Card Electrophysiol. 2013;38:179–85.CrossRef Akkaya M, Roukoz H, Adabag S, et al. Improvement of left ventricular diastolic function and left atrial reverse remodeling after catheter ablation of premature ventricular complexes. J Interv Card Electrophysiol. 2013;38:179–85.CrossRef
11.
go back to reference Park Y, Kim S, Shin J, et al. Frequent premature ventricular complex is associated with left atrial enlargement in patients with normal left ventricular ejection fraction. Pacing Clin Electrophysiol. 2014;37:1455–61.CrossRef Park Y, Kim S, Shin J, et al. Frequent premature ventricular complex is associated with left atrial enlargement in patients with normal left ventricular ejection fraction. Pacing Clin Electrophysiol. 2014;37:1455–61.CrossRef
12.
go back to reference Wojdyła-Hordyńska A, Pruszkowska-Skrzep P, Sommer P, et al. Does the origin of ablated premature ventricular contractions determine the level of left ventricular function improvement? Kardiol Pol. 2020;78(5):438–46.CrossRef Wojdyła-Hordyńska A, Pruszkowska-Skrzep P, Sommer P, et al. Does the origin of ablated premature ventricular contractions determine the level of left ventricular function improvement? Kardiol Pol. 2020;78(5):438–46.CrossRef
13.
go back to reference St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107(15):1985–90.CrossRef St John Sutton MG, Plappert T, Abraham WT, et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation. 2003;107(15):1985–90.CrossRef
14.
go back to reference Ypenburg C, Lancellotti P, Tops LF, et al. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol. 2007;50(21):2071–7.CrossRef Ypenburg C, Lancellotti P, Tops LF, et al. Acute effects of initiation and withdrawal of cardiac resynchronization therapy on papillary muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol. 2007;50(21):2071–7.CrossRef
15.
go back to reference Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;124(14):1527–36.CrossRef Goldenberg I, Moss AJ, Hall WJ, et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation. 2011;124(14):1527–36.CrossRef
16.
go back to reference Gold MR, Daubert C, Abraham WT, et al. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015;12(3):524–30.CrossRef Gold MR, Daubert C, Abraham WT, et al. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015;12(3):524–30.CrossRef
17.
go back to reference Kloosterman M, Rienstra M, Mulder BA, et al. Atrial reverse remodelling is associated with outcome of cardiac resynchronization therapy†. EP Europace. 2016;18(8):1211–9.CrossRef Kloosterman M, Rienstra M, Mulder BA, et al. Atrial reverse remodelling is associated with outcome of cardiac resynchronization therapy†. EP Europace. 2016;18(8):1211–9.CrossRef
18.
go back to reference Mathias A, Moss Arthur J, McNitt S, et al. Clinical implications of complete left-sided reverse remodeling with cardiac resynchronization therapy. J Am Coll Cardiol. 2016;68(12):1268–76.CrossRef Mathias A, Moss Arthur J, McNitt S, et al. Clinical implications of complete left-sided reverse remodeling with cardiac resynchronization therapy. J Am Coll Cardiol. 2016;68(12):1268–76.CrossRef
Metadata
Title
Effect of single ventricular premature contractions on response to cardiac resynchronization therapy
Authors
Eperke Dóra Merkel
András Mihaly Boros
Walter Richárd Schwertner
Anett Behon
Attila Kovács
Bálint Károly Lakatos
László Gellér
Annamária Kosztin
Béla Merkely
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2022
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-022-02725-3

Other articles of this Issue 1/2022

BMC Cardiovascular Disorders 1/2022 Go to the issue